Updated FL Tool
An Updated Interactive Treatment Decision Support Tool for Follicular Lymphoma
Christopher R. Flowers
Christopher R. Flowers, MD, MS

Pretest

Progress
1 2
Course Completed
Please answer the questions below.
1.

In the PURPOSE 1 study in cisgender women, compared with background HIV incidence, HIV incidence was:

2.

Your colleague asks you whether there are data to support efficacy and acceptability to use LA CAB + RPV in adolescents with HIV. You tell them that, at Wk 48 of the IMPAACT 2017 study, there were:

3.

Your colleague asks about evidence behind switching a virologically suppressed person to an INSTI-based regimen. You advise them that, in the PASO-DOBLE study, switching to DTG/3TC compared with BIC/FTC/TAF resulted in:

4.

I am familiar with data from the AIDS 2024 conference, and I plan to translate these data into current or future management strategies.